Yaneli Juárez-Vicuña

Dr. Yaneli Juárez-Vicuña

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Non-coding RNA Research
Verified
Journal Article
Open access
YJYaneli Juárez-Vicuña
Yaneli Juárez-Vicuña
DRDayanara Ruiz-Ojeda
Dayanara Ruiz-Ojeda
JGJavier González-Ramírez
Javier González-Ramírez
XFXimena Flores-Balderas
Ximena Flores-Balderas
RSRASHIDI SPRINGALL
RASHIDI SPRINGALL
CGCarlos Alfonso Guzmán-Martín
Carlos Alfonso Guzmán-Martín
Keratinocytes, the principal epidermal cells, play a vital role in maintaining the structural integrity and functionality of the skin. Beyond their protective role, keratinocytes are key contributors to the process of wound healing, as they migrate to injury sites, proliferate, and generate new layers of epidermis, facilitating tissue repair and remodeling. Moreover, keratinocytes actively participate in the skin's immune responses, expressing pattern recognition receptors (PRRs) to detect microbial components and interact with immune cells to influence adaptive immunity. Keratinocytes express a diverse repertoire of signaling pathways, transcription factors, and epigenetic regulators to regulate their growth, differentiation, and response to environmental cues. Among these regulatory elements, long non-coding RNAs (lncRNAs) have emerged as essential players in keratinocyte biology. LncRNAs, including MALAT1, play diverse roles in gene regulation and cellular processes, influencing keratinocyte proliferation, differentiation, migration, and response to environmental stimuli. Dysregulation of specific lncRNAs such as MALAT1 can disrupt keratinocyte homeostasis, leading to impaired differentiation, compromised barrier integrity, and contributing to the pathogenesis of various skin disorders. Understanding the intricate interplay between lncRNAs and keratinocytes offers promising insights into the molecular underpinnings of skin health and disease, with potential implications for targeted therapies and advancements in dermatological research. Hence, our objective is to provide a comprehensive summary of the available knowledge concerning keratinocytes and their intricate relationship with MALAT1.

11 November 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
CGCarlos Alfonso Guzmán-Martín
Carlos Alfonso Guzmán-Martín
YJYaneli Juárez-Vicuña
Yaneli Juárez-Vicuña
ADAarón Domínguez-López
Aarón Domínguez-López
JGJavier González-Ramírez
Javier González-Ramírez
LALuis M Amezcua-Guerra
Luis M Amezcua-Guerra
Fausto Sanchez-MunozFausto Sanchez-Munoz
Fausto Sanchez-Munoz

23 April 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
YJYaneli Juárez-Vicuña
Yaneli Juárez-Vicuña
CGCarlos Alfonso Guzmán-Martín
Carlos Alfonso Guzmán-Martín
LMLaura A. Martínez-Martínez
Laura A. Martínez-Martínez
Adrián Hernández-DíazcouderAdrián Hernández-Díazcouder
Adrián Hernández-Díazcouder
CHClaudia Huesca-Gómez
Claudia Huesca-Gómez
Fausto Sanchez-MunozFausto Sanchez-Munoz
Fausto Sanchez-Munoz

6 May 2022 in Clinical and Experimental Rheumatology
Verified
Journal Article
Closed access
LALuis M. Amezcua-Guerra
Luis M. Amezcua-Guerra
FSFausto Sánchez-Muñoz
Fausto Sánchez-Muñoz
EPEdgar Pichardo-Ontiveros
Edgar Pichardo-Ontiveros
JGJavier González-Ramírez
Javier González-Ramírez
LMLaura Aline Martínez-Martínez
Laura Aline Martínez-Martínez
YJYaneli Juárez-Vicuña
Yaneli Juárez-Vicuña
Full Papers; Authors: L.M. Amezcua-Guerra, F. Sánchez-Muñoz, E. Pichardo-Ontiveros, J. González-Ramírez, L.A. Martínez-Martínez, Y. Juárez-Vicuña

30 August 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
BABrianda Amezcua-Guerra
Brianda Amezcua-Guerra
LALuis M. Amezcua-Castillo
Luis M. Amezcua-Castillo
JGJazmín A. Guerra-López
Jazmín A. Guerra-López
KDKietseé A. Díaz-Domínguez
Kietseé A. Díaz-Domínguez
JGJosé Luis Sánchez Gloria
José Luis Sánchez Gloria
LALuis M Amezcua-Guerra
Luis M Amezcua-Guerra
Prompt diagnosis of ST-segment elevation myocardial infarction (STEMI) is essential for initiating timely treatment. MicroRNAs have recently emerged as biomarkers in cardiovascular diseases. This study aimed to evaluate the discriminatory capacity of serum microRNAs in identifying an ischemic origin in patients presenting with chest discomfort to the Emergency Department. The study included 98 participants (78 with STEMI and 20 with nonischemic chest discomfort). Significant differences in the expression levels of miR-133b, miR-126, and miR-155 (but not miR-1, miR-208, and miR-208b) were observed between groups. miR-133b and miR-155 exhibited 97% and 93% sensitivity in identifying STEMI patients, respectively. miR-126 demonstrated a specificity of 90% in identifying STEMI patients. No significant associations were found between microRNAs and occurrence of major adverse cardiovascular events (MACE). However, patients with MACE had higher levels of interleukin (IL)-15, IL-21, IFN-γ-induced protein-10, and N-terminal pro B-type natriuretic peptide compared to non-MACE patients. Overall, there were significant associations among the expression levels of microRNAs. However, microRNAs did not demonstrate associations with either inflammatory markers or cardiovascular risk scores. This study highlights the potential of microRNAs, particularly miR-133b and miR-126, as diagnostic biomarkers for distinguishing patients with STEMI from those presenting with nonischemic chest discomfort to the Emergency Department.

25 October 2023 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
LALuis M Amezcua-Guerra
Luis M Amezcua-Guerra
Fausto Sanchez-MunozFausto Sanchez-Munoz
Fausto Sanchez-Munoz
SGSantiago Guzmán-García
Santiago Guzmán-García
RMRicardo Márquez-Velasco
Ricardo Márquez-Velasco
Enrique Becerril VillanuevaEnrique Becerril Villanueva
Enrique Becerril Villanueva
YJYaneli Juárez-Vicuña
Yaneli Juárez-Vicuña
Objective Rhupus is a rare disease that shares characteristics of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). While several studies have explored the clinical and immunological profiles of patients with rhupus, the underlying cause of the disease remains unknown due to its complex pathogenesis. The objective of this study was to investigate the role of tumour necrosis factor (TNF) in the production of inflammatory molecules by peripheral blood mononuclear cells (PBMCs) from patients with rhupus. Methods The study involved five healthy controls, seven patients with rhupus and seven patients with SLE. PBMCs were obtained from each participant and stimulated with recombinant human TNF for 24 hours. The levels of various molecules secreted by the cells, such as cytokines and chemokines, were measured using immunobead-based assays on xMAP technology. Results The production levels of some molecules were higher in TNF-stimulated PBMCs from patients with rhupus and SLE than in unstimulated cells. In addition, the levels of certain molecules, including gp130/sIL-6Rb, a proliferation-inducing ligand (APRIL), interferon-β, matrix metalloproteinase-3 and interleukin (IL)-12, were higher in PBMCs from patients with rhupus even without TNF stimulation. Similarly, the levels of gp130/sIL-6Rb and APRIL were higher in TNF-stimulated PBMCs from patients with rhupus than in healthy controls. These results were further validated against patients with RA using enzyme-linked immunosorbent assay. Conclusions These findings suggest that the spontaneous production of molecules by cells from patients with rhupus may contribute to the development of the disease, and that TNF may play a role in this process by regulating the secretion of gp130/sIL-6Rb and APRIL.